Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

BeOne Medicines Q3 2026 Results: Net Income $385M, Up 208.2% YoY

BeOne Medicines Ltd. reported significant growth for the quarter ended September 30, 2026, with total revenues increasing to $1.89 billion from $1.41 billion in the prior year. Net income rose substantially to $384.7 million, or $3.28 per diluted ADS, driven by strong product sales and improved operating leverage despite increased R&D and SG&A spending.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue1,889.81,412.3
Gross profit1,672.91,215.8
Profit before tax410.4147.2
Net income384.7124.8
EPS (diluted, $ a share)$0.25$0.08

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Net income, year on year+208.2%
Revenue, year on year+33.8%
Gross margin88.5%
Operating margin22.2%
Source

10-Q filed with the SEC, NASDAQ: ONC. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

BeOne Medicines Ltd.: key numbers

Share price
$411.29Close, Nov 16
Shares outstanding
1.48BLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from BeOne Medicines Ltd.

All →
5:00 PM ET Form 4
Insider Selling

BeOne Medicines Principal Accounting Officer Titus B. Ball Sells $632K of Stock

Titus B. Ball, Principal Accounting Officer, sold 1,559 shares of BeOne Medicines Ltd. at $405.55 to $406.34 a share (average $405.57) in 2 transactions, worth $632K in total on Nov 6, 2026. Shares held after the trade: 0 (-100.0%).

Value
$632K
Shares
1,559
Average price
$405.57
Role
Principal Accounting Officer
Holding change
-100.0%
Trade date
Nov 6, 2026
5:14 PM ET Form 4
Insider Selling

BeOne Medicines SVP, General Counsel Chan Henry Lee Sells $447K of Stock

Chan Henry Lee, SVP, General Counsel, sold 1,115 shares of BeOne Medicines Ltd. at $400.00 to $402.00 a share (average $400.82) in 2 transactions, worth $447K in total on Nov 5, 2026. Shares held after the trade: 0 (-100.0%).

Value
$447K
Shares
1,115
Average price
$400.82
Role
SVP, General Counsel
Holding change
-100.0%
Trade date
Nov 5, 2026
6:06 AM ET 8-K
Financial Results

BeOne Medicines Financial Results

BeOne Medicines reported third quarter 2026 total global revenues of $1.9 billion, a 34% increase year-over-year, driven by strong sales of its BTK inhibitor BRUKINSA. The company achieved GAAP net income of $384.7 million and raised its full-year 2026 revenue guidance to a range of $6.9 billion to $7.0 billion.

Term
3 months

“Our strong third quarter results and raised full-year guidance reflect continued rapid global growth and leadership in hematology, anchored by our foundational BTK inhibitor BRUKINSA, which drives powerful and sustained responses in patients, and now joined by our next-generation BCL2 inhibitor BEQALZI.”

John V. Oyler, Co-Founder, Chairman, and CEO
5:05 PM ET Form 4
Insider Selling

BeOne Medicines Insider Xiaodong Wang Sells $11.3M of Stock

Xiaodong Wang sold 31,028 shares of BeOne Medicines Ltd. at $355.56 to $366.22 a share (average $362.97) in 11 transactions, worth $11.3M in total on Oct 27, 2026. Shares held after the trade: 0 (-100.0%).

Value
$11.3M
Shares
31,028
Average price
$362.97
Holding change
-100.0%
Trade date
Oct 27, 2026
5:09 PM ET Form 4
Insider Selling

BeOne Medicines Insider Xiaodong Wang Sells $10.9M of Stock

Xiaodong Wang sold 31,027 shares of BeOne Medicines Ltd. at $349.56 to $353.24 a share (average $350.99) in 5 transactions, worth $10.9M in total on Oct 13, 2026. Shares held after the trade: 0 (-100.0%).

Value
$10.9M
Shares
31,027
Average price
$350.99
Holding change
-100.0%
Trade date
Oct 13, 2026
4:53 PM ET Form 4
Insider Selling

BeOne Medicines SVP, General Counsel Chan Henry Lee Sells $418K of Stock

Chan Henry Lee, SVP, General Counsel, sold 1,115 shares of BeOne Medicines Ltd. at $375.00 a share, worth $418K in total on Sep 30, 2026. Shares held after the trade: 0 (-100.0%).

Value
$418K
Shares
1,115
Price
$375.00
Role
SVP, General Counsel
Holding change
-100.0%
Trade date
Sep 30, 2026

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.